Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology

(2017) Antonia R. Sepulveda et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Cancer immunotherapy: the beginning of the end of cancer?

(2016) Sofia Farkona et al.   BMC Medicine

HSP110T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer

(2016) Olivier Buhard et al.   JOURNAL OF MEDICAL GENETICS

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

(2014) S. Venderbosch et al.   CLINICAL CANCER RESEARCH

Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer

(2014) Van Morris et al.   Clinical Colorectal Cancer

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

(2012) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunohistochemical Staining for DNA Mismatch Repair Proteins in Intestinal Tract Carcinoma

(2011) Jinru Shia et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Cancer Immunotherapy Comes of Age

(2011) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Clinical Relevance of Microsatellite Instability in Colorectal Cancer

(2010) Albert de la Chapelle et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

(2009) M Koopman et al.   BRITISH JOURNAL OF CANCER

Pathologic Predictors of Microsatellite Instability in Colorectal Cancer

(2008) Joel K. Greenson et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Molecular Characterization of MSI-H Colorectal Cancer by MLHI Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation Screening

(2008) J. N. Poynter et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemistry versus Microsatellite Instability Testing For Screening Colorectal Cancer Patients at Risk For Hereditary Nonpolyposis Colorectal Cancer Syndrome

(2008) Jinru Shia   JOURNAL OF MOLECULAR DIAGNOSTICS